These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25010585)

  • 1. Trends in pharmacy compounding for women's health in North Carolina: focus on vulvodynia.
    Corbett SH; Cuddeback G; Lewis J; As-Sanie S; Zolnoun D
    South Med J; 2014 Jul; 107(7):433-6. PubMed ID: 25010585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy.
    McBane SE; Borgelt LM; Barnes KN; Westberg SM; Lodise NM; Stassinos M
    Pharmacotherapy; 2014; 34(4):410-23. PubMed ID: 24390902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compounded or confused? Bioidentical hormones and menopausal health.
    Huntley AL
    Menopause Int; 2011 Mar; 17(1):16-8. PubMed ID: 21427420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compounded bioidentical menopausal hormone therapy.
    ;
    Fertil Steril; 2012 Aug; 98(2):308-12. PubMed ID: 22831824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioidentical hormone therapy: a review of the evidence.
    Cirigliano M
    J Womens Health (Larchmt); 2007 Jun; 16(5):600-31. PubMed ID: 17627398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.
    L'Hermite M
    Climacteric; 2017 Jun; 20(3):205-211. PubMed ID: 28509626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.
    Santoro N; Braunstein GD; Butts CL; Martin KA; McDermott M; Pinkerton JV
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1318-43. PubMed ID: 27032319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "If sex hurts, am I still a woman?" the subjective experience of vulvodynia in hetero-sexual women.
    Ayling K; Ussher JM
    Arch Sex Behav; 2008 Apr; 37(2):294-304. PubMed ID: 17876696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounding for women's health: a compounder's perspective - need, regulations, and future.
    Boomsma D; Lahoud G
    Climacteric; 2021 Feb; 24(1):32-37. PubMed ID: 33135943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioidentical hormones for menopausal therapy.
    Sites CK
    Womens Health (Lond); 2008 Mar; 4(2):163-71. PubMed ID: 19072518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioidentical hormone therapy in menopause: relevance in dermatology.
    Borda LJ; Wong LL; Tosti A
    Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women with vulvodynia: awareness and knowledge of its care among student healthcare staff.
    Törnävä M; Koivula M; Helminen M; Suominen T
    Scand J Caring Sci; 2018 Mar; 32(1):241-252. PubMed ID: 28524242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy.
    Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):411-5. PubMed ID: 22825109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the concerns about custom-compounded "bioidentical" hormone therapy?
    Pinkerton JV
    Menopause; 2014 Dec; 21(12):1298-300. PubMed ID: 25387347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioidentical hormone therapy: a panacea that lacks supportive evidence.
    Boothby LA; Doering PL
    Curr Opin Obstet Gynecol; 2008 Aug; 20(4):400-7. PubMed ID: 18660693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vulvodynia, "A Really Great Torturer": A Mixed Methods Pilot Study Examining Pain Experiences and Drug/Non-drug Pain Relief Strategies.
    Schlaeger JM; Pauls HA; Powell-Roach KL; Thornton PD; Hartmann D; Suarez ML; Kobak WH; Hughes TL; Steffen AD; Patil CL
    J Sex Med; 2019 Aug; 16(8):1255-1263. PubMed ID: 31204266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability and validity of self-reported symptoms for predicting vulvodynia.
    Reed BD; Haefner HK; Harlow SD; Gorenflo DW; Sen A
    Obstet Gynecol; 2006 Oct; 108(4):906-13. PubMed ID: 17012453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy.
    Moehring RW; Lewis SS; Isaacs PJ; Schell WA; Thomann WR; Althaus MM; Hazen KC; Dicks KV; Lipuma JJ; Chen LF; Sexton DJ
    JAMA Intern Med; 2014 Apr; 174(4):606-12. PubMed ID: 24493147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.